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Background: Neuromyelitis optica (NMO) is a chronic autoimmune disease of the central nervous system (CNS).
The main immunological feature of the disease is the presence of autoantibodies to Aquaporin 4 (AQP4+), identified in
about 82 % of cases. Currently, there are no reliable biomarkers for monitoring treatment response in patients with
NMO. In an effort to identify biomarkers, we analyzed microRNAs (miRNAs) in the blood of rituximab-treated NMO
patients before and after therapy.
Methods: Total RNA extracted from whole blood of nine rituximab-responsive NMO patients before and 6 months
following treatment was subjected to small RNAseq analysis. The study included an additional group of seven untreated
AQP4+ seropositive NMO patients and 15 healthy controls (HCs).
Results: Fourteen miRNAs were up regulated and 32 were downregulated significantly in the blood of NMO patients
following effective therapy with rituximab (all p < 0.05). Furthermore, we show that expression of 17 miRNAs
was significantly higher and of 25 miRNAs was significantly lower in untreated NMO patients compared with
HCs (all p < 0.05). Following rituximab treatment, the expression levels of 10 of the 17 miRNAs that show
increased expression in NMO reverted to the levels seen in HCs. Six of these “normalized” miRNAs are known as
brain-specific/enriched miRNAs.
Conclusions: Specific miRNA signatures in whole blood of patients with NMO might serve as biomarkers for
therapy response. Furthermore, monitoring the levels of brain-specific/enriched miRNAs in the blood might
reflect the degree of disease activity in the CNS of inflammatory demyelinating disorders.
Keywords: Brain-specific microRNAs, Circulating biomarkers, Rituximab, Aquaporin 4 (AQP4), Neuromyelitis
optica (NMO)Background
Neuromyelitis optica (NMO) is a chronic inflammatory
disease of the central nervous system (CNS), whose clinical
features include mainly acute attacks of bilateral or rapidly
sequential optic neuritis (eventually leading to visual loss in
many patients), and transverse myelitis. Disease etiology of
NMO is still unknown. However, it is known that the* Correspondence: adembinsky@gmail.com
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humoral immune system and primarily target astrocytes
[1, 2]. The most important evidence of this was the identi-
fication of the NMO-IgG antibody, anti-Aquaporin-4;
NMO-IgG antibodies identify about 82 % of patients. At
present, it is challenging to diagnose NMO patients that
are negative for this marker from patients with other CNS
demyelinating diseases, especially multiple sclerosis (MS).
Micro RNAs (miRNAs) function to modify the expres-
sion of target genes. miRNA-mediated gene regulation is
critical during many biological processes including
inflammation and neurodegeneration. Because each
miRNA can regulate many target genes, the biologicalle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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erable. Recent research has shown that miRNAs have
potential as non-invasive biomarkers for the diagnosis and
prognosis of disease as well as monitoring of treatment
response [3]; miRNAs also represent promising novel
targets for therapy [1]. Extracellular circulating miRNAs
are remarkably stable [4]. Their stability is achieved via
different mechanisms. They can be packaged in micro-
particles (exosomes, microvesicles, and apoptotic bod-
ies) [5–7] or associated with RNA-binding proteins
(Argonaute2 [Ago2]) or lipoprotein complexes (high-
density lipoprotein [HDL]) [8] to prevent their degrad-
ation. The stability of miRNAs, coupled with advances
in high-throughput technologies that provide the abil-
ity to perform a global analysis of miRNA expression
profiling, has positioned miRNAs as ideal biomarker
candidates. Recently, altered miRNA expression has
been reported in several human autoimmune diseases,
and miR-92a was suggested as a circulating biomarker
for disease staging in MS. The single study on miRNAs in
NMO revealed that several miRNAs have distinct expres-
sion levels in NMO patients compared with healthy con-
trols (HCs) and patients with MS [9]. But, additional more
comprehensive studies are needed to establish these
miRNAs as diagnostic markers.
Currently, the most commonly used treatments in
NMO are steroids, azathioprine, mycophenolate mofetil,
and rituximab [10–13]. Rituximab is a chimeric anti-CD20
monoclonal antibody that depletes B cells. It is commonly
used for treating B cell lymphoma and has been found to
be effective in the treatment of autoimmune rheumato-
logical and neurological conditions including NMO. Rituxi-
mab is currently considered the most effective therapy for
preventing NMO exacerbations [14, 15]. No definite bio-
marker of response to therapy is presently available for
monitoring patients with NMO. Current data relating to
the correlation between AQP4-IgG titers and disease activ-
ity in the long-term course of NMO are inconsistent [16].
In this study, we aimed to identify miRNA biomarkers
in the peripheral blood of patients with NMO and to
monitor treatment response. We examined whether ana-
lysis of global miRNA expression in the blood of patients
with NMO before and after treatment with rituximab
could identify a distinct miRNA expression signature asso-
ciated with therapy. This putative signature could serve as
a predictor for response to therapy, with the goal of assist-
ing in the individualized management of this disease.
Methods
Subjects
The patient cohort included 16 patients with NMO (14
females, two males; age 41 ± 14.3 years; disease duration,
5.3 ± 6.2 years; Expanded Disability Status Scale (EDSS),
4.8 ± 1.8), followed at the Hadassah MS Center. Therelapse rate in the 2 years prior to the study was 1.25 ±
0.7. None of the enrolled patients had relapse or were
treated with steroids for at least 30 days before their
blood samples were drawn. 82.3 % of the NMO patients
were positive for anti-AQP4. Brain magnetic resonance
imaging (MRI) was normal or compatible with the diag-
nosis of NMO in all patients, and spinal MRIs revealed
long extensive myelitis in 14/16 patients. None of the
nine responders had relapses in the 2 years following
rituximab therapy. Five patients with treatment failure
had comparable clinical characteristics to the responders
but experienced no decrease in relapse rate with rituxi-
mab therapy (four females, one male; age 46 ± 10.7 years;
disease duration, 5.2 ± 4.0 years; EDSS, 5.2 ± 4.4; relapse
rate in the 2 years prior to the study, 1.3 ± 0.44). The
patients signed informed consent. Clinical data were
collected from patients’ files. NMO patients were
diagnosed according to the NMO diagnostic criteria
[17]. An age- and sex-matched control group com-
prised 15 healthy individuals (10 females, 5 males; age
36.7 ± 9.4 years).
NMO-Ig seropositivity in the study cohort was deter-
mined using RSR ELISA assay in sera. The anti-AQP4
ELISA positive samples were also assessed using a cell-
based assay (Euroimmun).Blood RNA isolation and miRNA quantification
A 4-ml blood sample was collected in EDTA tubes from
each patient. Two hundred fifty microliters of whole
blood was mixed with 750 μl of Tri-reagent BD (Sigma),
supplemented with 20 μl of 5 N acetic acid, and frozen.
RNA was extracted according to the manufacturer’s
instructions. Gel electrophoresis confirmed the integrity
of the RNA, and total RNA was quantified using Qubit
2.0 (Thermo Fisher Scientific Inc.).Small RNA sequencing
Total RNA was subjected to multiplexed small RNA
cDNA library preparation. Library preparation entails
ligation of barcoded 3′ adapters to 20 different samples,
pooling of samples, ligation of a 5′ adapter, reverse
transcription and polymerase chain reaction (PCR), as
previously described [18], with modifications allowing
multiplexing of several 20-sample libraries on a single
HiSeq lane, namely, 40–100 small RNA libraries per
lane. Libraries were sequenced on an Illumina HiSeq
sequencer, and the information obtained was analyzed
by an automated computer pipeline to decode and an-
notate small RNA reads [19]. Normalization of miRNA
reads was performed by dividing each miRNA read
frequency by the total number of miRNA sequence
reads within the subsample, thereby correcting the
variable sequencing depth in each subsample.
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Mature miRNAs were quantified using Perfecta® microRNA
Assays (Quanta Biosciences), according to the manufac-
turer’s instructions. Real-time polymerase chain reaction
(PCR) was performed on a StepOne real-time reverse tran-
scription (RT)-PCR (Life Technologies) in triplicate for
each sample. The fold changes of miRNAs were normalized
to RNU6B, (ΔCT). The data is presented as 2−ΔCT. Primer
sequences were designed based on the miRNA sequences
obtained from the miRBase database (http://microrna.
sanger.ac.uk/). Statistical significance was calculated using
two-tailed t test.
Statistical analysis
Statistical procedures on count data were based on DESeq2,
a publically available R/Bioconductor package for analysis
of differential expression in RNA sequencing experiments
[20], as previously described [21].
Results
Identification of differentially expressed microRNAs
before and after rituximab treatment and between HCs
and patients with NMO
The main aim of our study was to identify miRNAs that
are differentially expressed before and after rituximab
treatment. Rituximab is the most effective therapy for
patients with NMO, with a response rate of approxi-
mately 90 % [22, 23]. Blood samples were collected from
nine NMO patients, classified as rituximab responders,
prior to and at 6 months following therapy and from 15
age- and sex-matched HCs. To further analyze the dif-
ferential expression between untreated NMOs and HCs,
seven additional untreated seropositive NMO patients
were also included in the study. Total RNA was extracted
from the whole blood samples, and miRNA levels were
quantified by deep sequencing analysis (RNAseq).
RNAseq results demonstrated that the expression
levels of 32 miRNAs were decreased and of 14 miRNAs
were increased significantly (p < 0.05) in the nine treated
NMO patients following treatment with rituximab (Table 1).
These nine samples from responders were further com-
pared with those from five non-responders. Using real-time
RT-PCR, we were able to show that miR-125 was sig-
nificantly different for rituximab responders and non-
responders (p = 0.03). The additional eight miRNAs
that were analyzed were differently expressed in non-
responders, but the differences were not statistically
significant, most likely due to the small number of non-
responders in our cohort. (Data from the three most
significant miRNAs are presented in Additional file 1:
Figure S1).
Analysis of the differential expression between the 16
untreated NMO patients and 15 HCs demonstrated that
expression levels were significantly lower for 25 miRNAsand significantly higher for 17 miRNAs in NMO patients
compared with HCs (Table 2). Notably, the expression
levels for 10 out of the 17 miRNAs with significantly in-
creased expression in NMO patients reverted to the level
of HCs following therapy with rituximab (Table 1, Fig. 1a).
In addition, miR-7 and miR-124, which had lower expres-
sion in NMO patients, reverted to the level of HCs follow-
ing therapy with rituximab (Table 1, Fig. 1b).
Discussion
Our results demonstrate for the first time that a set of
miRNAs with elevated expression in the blood of NMO
patients revert to the levels of matched healthy controls
following effective therapy with rituximab. The majority
of these “normalized” miRNAs are known as brain-specific/
enriched miRNAs. Following further validation, the results
of this study might lead to the establishment of a diagnostic
test to monitor treatment response in NMO.
The six brain-enriched miRNAs, miR-135a, miR-135b,
miR-125b, miR-134, miR-138, and miR-760 [24–27], that
revert to healthy control levels after treatment are
expressed abundantly or predominantly in the brain.
The higher quantity of these miRNAs in the circulation
of patients with NMO might imply that they were shed
to the circulation by degenerative brain cells, with a cor-
responding decrease in the amount of these miRNAs in
the circulation observed following treatment, when the
destructive inflammatory process diminishes. Therefore,
monitoring the levels of brain-specific/enriched miRNAs
in the blood might reflect the degree of disease activity
in the CNS of demyelinating disorders.
miRNAs are highly stable elements that can be de-
tected in body fluids as well as in different blood cells
[28]. Their stability, along with the recent development
of sensitive detection and quantification methods, has
positioned miRNAs as great candidate biomarkers for
diagnosis of specific diseases. Moreover, miRNAs might
play a major role in initiating and/or maintaining auto-
immunity processes [29, 30].
For many years, NMO was considered as a severe vari-
ant of MS [1]. Both diseases have autoimmune inflamma-
tory lesions in the CNS. In MS, there is an abundance of
data on miRNA expression in whole blood, peripheral
blood mononuclear cells (PBMCs), plasma, cerebrospinal
fluid (CSF), and peripheral blood T cells [31–34]. It is
widely accepted that miRNAs are dysregulated in MS, but
their use as biomarkers is still evolving [31]. In a recently
published review on the available data regarding miRNAs
in MS, Xinting et al. summarized that miR-15a, miR-19a,
miR-22, miR-210, and miR-223 were upregulated in T-reg
cells, plasma, blood cells, PBMCs, and brain white matter
tissues from MS patients; miR-21, miR-142-3p, miR-146a,
miR-146b, miR-155, and miR-326 were upregulated and
miR-181c and miR-328 were downregulated in PBMCs
Table 1 Differential expression of miRNAs following rituximab therapy
Upregulated miRNAs Downregulated miRNAs
miRNA treated vs untreated Fold change p value miRNA treated vs untreated Fold change p value
hsa-miR-16 1.99 0.00001 hsa-miR-125b (#^) 0.17 0.00001
hsa-miR-15a 2.65 0.00001 hsa-miR-760 (#^) 0.08 0.00005
hsa-miR-124 6.42 0.00012 hsa-miR-135a (#^) 0.18 0.00058
hsa-miR-26b 1.91 0.00044 hsa-miR-134 (#^) 0.1 0.00183
hsa-miR-7 3.8 0.00085 hsa-miR-138 (#^) 0.18 0.00515
hsa-miR-15b 1.79 0.00206 hsa-miR-423-3p (#) 0.4 0.00734
hsa-miR-451 1.85 0.00233 hsa-miR-100 (#) 0.31 0.00818
hsa-miR-454 2.09 0.00458 hsa-miR-125a 0.24 0.00925
hsa-miR-17 1.66 0.00735 hsa-miR-135b(#^) 0.18 0.01455
hsa-miR-144 2.13 0.01293 hsa-miR-203 (#) 0.2 0.01629
hsa-miR-1180 3.53 0.01837 hsa-miR-660 (#) 0.31 0.04582
hsa-miR-106a 1.71 0.01897 hsa-miR-30d 0.34 0.000002
hsa-miR-184 3.41 0.03243 hsa-miR-200c 0.09 0.00003



















miRNAs with increased expression in NMO patients that were normalized following rituximab therapy are indicated by (#); brain-specific/enriched miRNAs are
marked with (^)
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regulated in blood, peripheral T cells and B cells, or
plasma samples from MS patients. None of the upregu-
lated miRNAs were increased in our study; the distinct
miRNA expression profiles provide further support for the
concept that NMO has a distinct pathogenesis from MS.
In MS, there have been limited attempts to study the
use of miRNAs in treated versus untreated patients,
evaluating commonly used therapies. Waschbisch et al.
studied five miRNAs (miR-20b, miR-142-3p, miR-146a,
miR-155, and miR-326) by qPCR and found that therewas significantly lower expression of miR-142-3p and
miR-146a in glatiramer acetate (GA)-treated patients (no
differences in expression were detected between un-
treated and IFN-β-treated patients) [35]. In an investiga-
tion of miRNA and mRNA expression in PBMCs of MS
patients before and after IFN-β therapy, Hecker et al.
found that IFN-β-responsive genes were upregulated in
parallel to downregulation of miRNAs. Among the miR-
NAs, they identified altered expression among members
of the miR-29 family [36]. Given the low clinical re-
sponse rate of MS patients to IFN-β and GA therapy,
Table 2 Differential expression of miRNAs between untreated NMO patients and HCs
Upregulated miRNAs Downregulated miRNAs
miRNAs NMO vs HCs Fold change p value miRNAs NMO vs HCs Fold change p value
hsa-miR-760 (#^) 10.6 0.00021 hsa-miR-7 0.19 0.00034
hsa-miR-423-3p (#) 1.6 0.0008 hsa-miR-140 0.4 0.00042
hsa-miR-660 (#) 6.1 0.00118 hsa-miR-22 0.57 0.00108
hsa-miR-135a (#^) 5.3 0.00202 hsa-miR-143 0.11 0.00109
hsa-miR-135b (#^) 8 0.00329 hsa-miR-150 0.35 0.00126
hsa-miR-1180 2.8 0.00562 hsa-let-7b 0.51 0.00221
hsa-miR-203 (#) 6.5 0.00862 hsa-miR-2110 0.14 0.00541
hsa-miR-18a 1.7 0.01101 hsa-miR-29a 0.28 0.00612
hsa-miR-20b 1.9 0.01591 hsa-miR-342 0.24 0.0103
hsa-miR-100 (#) 2.8 0.02 hsa-miR-10b 0.21 0.01041
hsa-miR-205 6.5 0.0228 hsa-miR-1227 0.12 0.01501
hsa-miR-134 (#^) 4.6 0.02493 hsa-miR-21 0.54 0.01947
hsa-miR-542 6.5 0.03172 hsa-miR-133b 0.16 0.01964
hsa-miR-125b (#^) 1.7 0.0413 hsa-miR-532-5p 0.33 0.02214
hsa-miR-551b 5.7 0.04761 hsa-miR-30e 0.47 0.03266
hsa-miR-454 2.1 0.04839 hsa-miR-133a 0.24 0.03284









miRNAs with increased expression in NMO patients that were normalized following rituximab therapy are indicated by (#); brain-specific/enriched miRNAs are
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more effective MS therapy, natalizumab, Sievers et al.
found that 10 miRNAs, out of 1059 tested, were differ-
entially expressed in B cells of natalizumab-treated pa-
tients versus untreated patients and Ingwersen et al.
found that natalizumab therapy restored aberrant blood
miRNA expression profiles in MS patients [37, 38]. The
10 most strongly upregulated miRNAs from MS lesions
were expressed in astrocytes. This is noteworthy since in
NMO the autoantibodies that are directed against AQP4
are expressed by astrocytes. This supports the rationale
that miRNAs may contribute to pathogenesis of diseases
in which astrocytes play a major role, like NMO.
In contrast to MS, in NMO, there is only one recent
publication by Keller et al., which studied miRNAs in
the blood of patients [9]. Their study included 11 pa-
tients with NMO, 60 patients with MS, and 43 HCs.
They identified 141 differentially expressed miRNAs inNMO patients compared with HCs and 115 miRNAs in
NMO versus MS patients. These results did not concur
with the results from our study; not all the miRNAs that
were found by Keller et al. were detected in our study
and vice versa. The difference between the results of
these studies may be partly attributed to the differences
in patient cohorts. Our study included only untreated
patients while most of the patients in the Keller et al.
study were treated with immunosuppressive medica-
tions. Given the known influence of the immune system
on miRNAs [39], it is conceivable that miRNA expres-
sion profiles would differ in immunosuppressant-treated
and untreated patients. The use of different biostatistical
method analyses and different RNAseq library preparation
methods might also contribute to the different results [40].
Interestingly, one of the two RT-PCR-validated miRNAs
identified by Keller et al. [9] was also highly significant in
our cohort—miR-1180 (p = 0.005). Although our study
Fig. 1 Differential miRNA expression between healthy controls and NMO patients before and following rituximab therapy. RNA was extracted
from whole blood of 15 healthy controls and nine NMO patients before and after rituximab therapy, and miRNAs were quantified using deep
sequencing. The results of nine of the 10 miRNAs which revert to normal levels following rituximab therapy are presented in the figure as
normalized counts (logarithmic scale). Healthy controls, NMO patients before rituximab therapy and NMO patients after therapy are marked as
blue circles, dark red squares, and grey triangles, respectively
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patients and HCs, the main focus of our study was on dif-
ferential miRNA expression after treatment. Using this ana-
lysis, we found a clear signature of miRNA expression that
not only differed between NMO patients and HCs but also
reverted to normal in response to rituximab therapy. Our
study has its limitations and currently we cannot ascertain
whether some of the above described changes in themiRNA levels following rituximab therapy are secondary to
B cell depletion. It is noteworthy that the blood samples
taken at the 6-month time-point were taken following ana-
lysis of positive CD19 cell detection in the blood, indicating
that patients were not depleted of B cells. This supports the
idea that the miRNA signature could represent a distinct
phenomenon, rather than simply being a reflection of
decreased B cell counts.
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monly used therapy in NMO. Although most patients
with NMO have detectable anti-AQP4 autoantibodies in
the serum, the mechanism by which B cell-depleting ac-
tivity mediates the beneficial effect is not clearly under-
stood. Previous studies testing rituximab in NMO found
a high response rate and most of the patients remained
relapse free or experienced decreases in the annualized
relapse rate (ARR) (60–100 % of disease-free patients in
cohorts with 5–30 NMO patients) [22, 23].
Using 18 samples obtained from the nine responding
patients in our study (two from each participant), we
identified 46 miRNAs that significantly changed fol-
lowing rituximab therapy (p < 0.05) (Table 1). One of
the significantly changed miRNA is miR-125. This
miRNA has previously been described as a biomarker
of rituximab therapy in B cell lymphoma and rheuma-
toid arthritis (RA) [41]. These findings give further
validation to the authenticity of our analysis and sug-
gest that the effect of rituximab on miR-125 levels
may not be disease-specific.
Several attempts have been made to develop bio-
markers in order to individualize rituximab therapy in
NMO patients. CD19+ and CD27 + CD19 + B cell counts
were studied by Kim et al. in NMO patients treated with
rituximab [22, 42]. CD19 is expressed on B cells and
CD27 on memory B cells. They reported that monitor-
ing CD19- and CD27-positive B cell counts in the blood
could help dosing the next rituximab administration.
However, this assay of CD27-positive B cell suppression
by rituximab is not in widespread clinical use. Recently,
the same group found that, like in patients with non-
Hodgkin lymphoma and RA [43], NMO patients carry-
ing the V158F allele of the fragment c gamma receptor
3A (FCGR3A-F) have increased likelihood of incomplete
B cell depletion and fivefold increase chance of relapse
following rituximab treatment. This effect was more sig-
nificant in patients that were not treated previously with
methotrexate [43].
Conclusions
In conclusion, we identified a miRNA signature in
whole blood of patients with NMO. Following rituxi-
mab therapy, the expression levels of the majority of
miRNAs (10/17) that have higher expression in pa-
tients with NMO versus HCs revert to normal levels
following rituximab therapy. Our findings imply that
this miRNA signature may serve as a biomarker for
therapy response. Furthermore, six out of these “nor-
malized” miRNAs are brain-enriched miRNAs. Moni-
toring the levels of brain-specific miRNAs in the
blood of patients with inflammatory demyelinating
disorders may reflect the degree of disease activity in
the CNS.Additional files
Additional file 1: Figure S1. RNA was extracted from whole blood of
nine responders and five non-responders NMO patients 6 months following
Rituximab therapy and miRNAs were quantified using real-time RT PCR. The
results of 3 most significant differentially expressed miRNAs are presented in
the figure as 2^Δ ct. Responders are marked in dark red and non-responders
in grey. (DOCX 32 kb)
Additional file 2: Table S1. miRNA normalized counts in patients with
NMO. (XLSX 157 kb)
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